Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Hultcrantz, M., Larson, S., Liedtke, M., Martin, T., Omel, J., Shain, K., Sborov, D., Stockerl-Goldstein, K., Weber, D., Keller, J., Kumar, R. 2020; 18 (12): 1685–1717

Abstract

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.

View details for DOI 10.6004/jnccn.2020.0057

View details for PubMedID 33285522